Rheumatoid Arthritis News

Methotrexate use at the pre-arthritis stage of symptoms and subclinical inflammation fails to prevent clinical arthritis, but does improve symptoms and MRI-detected inflammation vs. placebo, according to data published in The Lancet.

The future of rheumatoid arthritis treatment has expanded beyond just managing the disease itself, according to Linda Li, PT, PhD, professor and Harold Robinson/Arthritis Society Chair in Arthritic Diseases at the University of British Columbia.

Sept. 14 marks the second annual ILD Day, which aims to increase awareness of interstitial lung diseases.

Most older adults with joint pain feel they can manage said pain without physician assistance, while 66% report they treat their joint pain with over-the-counter drugs such as acetaminophen or ibuprofen, according to a poll.

The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.

Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

Ozoralizumab, in either the 30 mg or 80 mg formulation, significantly reduces rheumatoid arthritis signs and symptoms in patients with an inadequate response to methotrexate, according to data published in Arthritis & Rheumatology.

Randomized controlled trials for rheumatoid arthritis in Canada often fail to report determinants of health inequity among their participants, according to data published in Arthritis Care & Research.

Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in patients with rheumatoid arthritis who were receiving methotrexate as a maintenance therapy, according to data.